Evercore ISI Group Upgrades Intellia Therapeutics to Outperform, Raises Price Target to $24
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsUpgradesPrice Target
Evercore ISI Group analyst Jonathan Miller upgrades Intellia Therapeutics (NASDAQ:NTLA) from In-Line to Outperform and raises the price target from $16 to $24.
Evercore ISI Group analyst Jonathan Miller upgrades Intellia Therapeutics (NASDAQ:NTLA) from In-Line to Outperform and raises the price target from $16 to $24.